Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (1083)	4/9/2002 9:49:57 AM
From: Michael Bakunin	Read Replies (1) \| Respond to of 2243

'Unimpressive, depressing' data is just what I'm worried about. I hate buying something I think is cheap and watching it get cheaper, and my guess is that dropping T64 would precipitate just that in the market. Long-time lurker, but thanks for the hello. -mb

To: scaram(o)uche who wrote (1083)	4/9/2002 9:35:33 PM
From: Miljenko Zuanic	Respond to of 2243

Rick, Regards the T67 I do not understand why they are going after hepatocelluar C? Cytotoxic agent(s) does very little in this cancer type, and very often do more damage than help. There are other refractory cancers that may respond to T67 (as well T607)? Maybe they are confident that survival benefit (I will not count on response rate at this time) will be sufficient and readily achievable? Why not completely switch to 607 if toxicity were reduced, compared to 67? <<We'll see, and my "basic" is that it's a very nice investment, inflammation, obesity, and lipid disorder programs.>> Do not get me wrong. TLRK is on high priority list. It is cheap. Programs (other than cancer) and science (chemistry and biology) is at high level. Maybe I am simple waiting that friends from East will throw few more bucks on short? Miljenko